Presidente Prudente

Researchers are evaluating the safety and effectiveness of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to understand how finerenone affects morbidity and mortality in this patient group. Participants will receive either oral finerenone or a matching oral placebo. The study focuses on patients currently hospitalized or recently discharged with heart failure symptoms and specific heart function measures. The trial is event-driven and will continue for up to approximately 30 months to collect sufficient data on outcomes. During the study, researchers will monitor the total number of heart failure events and cardiovascular deaths, as well as track serious adverse events and any adverse events that lead participants to stop the study drug. These ongoing assessments will help evaluate the overall safety and impact of the treatment over the duration of the trial.

Researchers are comparing the length of time participants survive without signs of cancer returning after treatment for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). This Phase 3 study focuses on patients who have received Bacillus Calmette-Guérin (BCG) treatment and have specific FGFR mutations or fusions. The study aims to evaluate and compare disease-free survival between those treated with TAR-210 and those receiving intravesical chemotherapy chosen by the investigator. Participants will receive either TAR-210, a drug administered directly into the bladder, or one of two chemotherapy drugs, Mitomycin C or Gemcitabine, also given intravesically. All visible tumors must be fully removed before randomization. The study includes patients who are either unresponsive to BCG, experienced with BCG, or intolerant to BCG treatment. Participants must not be eligible for or must refuse radical cystectomy surgery. During the study, participants will be monitored for disease-free survival for up to five years. Researchers will perform assessments including urine testing, tumor tissue analysis, and biopsies as needed to confirm eligibility and monitor disease status. Safety, treatment adherence, and patient health status will be regularly evaluated to ensure ongoing suitability for the study.

Researchers are investigating a treatment approach for patients hospitalized with community-acquired pneumonia (CAP), a condition with high rates of illness and death. This phase 3 trial compares therapeutic-dose heparin versus usual care pharmacological thromboprophylaxis to see if it improves patient outcomes. The study focuses on preventing complications caused by blood clots and inflammation that can worsen respiratory and organ function in CAP patients. Previous findings in COVID-19 pneumonia suggest heparin might reduce disease progression and mortality, but its effects in non-COVID-19 CAP are unknown. Participants will receive either therapeutic-dose heparin, preferably a low molecular weight heparin (LMWH) like enoxaparin, dalteparin, or tinzaparin, dosed by patient weight unless contraindicated. Intravenous unfractionated heparin (UFH) may be used instead, especially for those with kidney issues, with dosing adjusted to specific blood clotting targets. The trial is open-label and randomized, with adaptive rules to monitor progress. Usual care pharmacological thromboprophylaxis is the comparator. Treatment and monitoring occur during hospital admission, anticipated to last at least 72 hours after randomization. During the study, patients are assessed for survival at 30 days and monitored for complications related to CAP. Researchers collect clinical data including oxygen use, laboratory tests, and adverse events, tracking safety and effectiveness. The study excludes patients with active COVID-19, recent bleeding, contraindications to anticoagulation, or those receiving critical care interventions. Overall participation depends on hospital stay length and clinical status, with follow-up to evaluate the primary outcome of survival within a month.

Researchers are evaluating whether ziltivekimab can help people who were hospitalized due to a heart attack by potentially reducing the development of heart disease and preventing new heart attacks or strokes. This Phase 3 study compares ziltivekimab with a placebo, which is a dummy medicine that has no effect on the body. Both treatments are given by chance, with equal likelihood for participants to receive either ziltivekimab or placebo. Participants will inject the study medicine once a month under the skin in the stomach, thigh, or upper arm. Ziltivekimab is given as an initial loading dose followed by monthly maintenance doses. The placebo group receives a matching injection schedule. The study duration is about two years. During the study, researchers will monitor participants for the time until the first serious heart-related event, including cardiovascular death, non-fatal heart attack, or non-fatal stroke. Participants will be closely observed from the start of randomization up to 25 months. The study includes regular follow-ups to assess safety and effectiveness of the treatments throughout this period.

Resistance training is popular due to its health benefits, but performing it at high intensity can cause muscle stress, fatigue, and reduced performance. Researchers are evaluating blood flow restriction (BFR) as a recovery technique that may speed up muscle recovery after intense resistance exercise. This clinical trial focuses on understanding how different BFR pressures affect recovery after maximal resistance exercise. The study will randomly assign 80 healthy adults aged 18 to 35 years into four groups: BFR with 80% total occlusion pressure, BFR with 60% total occlusion pressure, BFR with 10 mmHg pressure, and a control group with no BFR. Each participant will complete initial assessments, undergo a muscle stress protocol, receive their assigned intervention continuously for 20 minutes, and have follow-up assessments immediately, and at 24, 48, and 72 hours after exercise. The interventions involve applying blood flow restriction devices at specified pressures. Participants will be evaluated on multiple outcomes including muscle pain, recovery perception, discomfort, effort, cellular integrity, pain threshold, muscle tone, stiffness, elasticity, muscle strength, and functional muscle power through various tests and scales. Data collection includes scales like the Numerical Rating Scale for pain, Likert scale for recovery and discomfort, Borg scale for effort, and tests like bioelectrical impedance analysis, myotonometry, dynamometry, and jump tests. The total participation duration covers repeated assessments over 72 hours post-exercise.

Researchers are evaluating how combining two recovery methods—active recovery (AR) and blood flow restriction (BFR)—may help amateur male runners recover after exercise. This study focuses on healthy males aged 18 to 40 who run at a pace faster than 5:30 min/km. The goal is to see if using both techniques together improves recovery outcomes better than active recovery alone or passive rest. Participants will be randomly assigned to one of three groups: active recovery with blood flow restriction using a pneumatic cuff at 60% occlusion pressure for 10 minutes, active recovery alone for 10 minutes, or passive rest as a control. Before and after a muscle stress test, participants will complete baseline and follow-up assessments immediately and at 24, 48, 72, and 96 hours post-exercise. Throughout the study, researchers will measure muscle strength, aerobic capacity, muscle power, soreness, pain threshold, recovery perception, muscle tone, and heart rate variability. Data will be collected using various tests and devices, including digital dynamometers, myotonometry, bioelectrical impedance analysis, and questionnaires. Participants will provide informed consent and may be asked about data use and sharing. The total follow-up period lasts 96 hours after exercise.

Researchers are studying the effects of L-arginine supplementation on how the body recovers its heart and lung functions after moderate exercise. L-arginine is an amino acid that helps produce nitric oxide, a substance involved in important processes like widening blood vessels, controlling blood flow, and supporting cellular energy. The study focuses on healthy male adults aged 18 to 30 who are physically active, aiming to clarify how L-arginine influences recovery after exercise. The study involves two stages, each conducted on a treadmill with at least 48 hours of rest in between. In one stage, participants take 3 grams of L-arginine capsules one hour before a submaximal exercise test. In the other, they consume a 3-gram placebo capsule made of starch before the same exercise test. The exercise includes warming up at 5 km/h followed by gradually increasing speed until reaching 80% of the estimated maximum heart rate. During both stages, heart rate, blood pressure, oxygen levels, and heart rate variability are monitored continuously. Participants will visit the lab in the late afternoon to early evening under controlled temperature and humidity. They will rest for an hour before exercise while initial measurements are taken, and then continue to be monitored for 20 minutes after exercising at specified times. Data collected includes cardiovascular and autonomic nervous system responses before, during, and after exercise to assess recovery. This careful monitoring helps researchers evaluate the potential effects of L-arginine on the body's response to physical activity.

This research aims to explore how lifestyle habits and health characteristics, such as physical activity and excess weight, relate between parents and their children or adolescents. It focuses on understanding if different types and intensities of physical activity among parents are connected to similar habits and health factors in their children. The study also considers other lifestyle factors like smoking, eating disorders, symptoms of anxiety and depression, and the presence of chronic diseases, examining how these may differ depending on the physical activity levels of parents. The study does not involve any interventions but observes the behaviors and health parameters of both parents and children. Researchers will evaluate various aspects of physical activity, including activities during work or school, leisure time, and active commuting, as well as intensities ranging from light to very vigorous. The study groups consist of physically active and insufficiently active parents and their children, aiming to identify possible relationships between their lifestyle habits and health status. Participants will be assessed for their physical activity levels using both objective and subjective measures at the start of the study. Researchers will also collect information about other lifestyle habits and health characteristics of both parents and children. The study includes children and adolescents over 6 years old, along with their adult parents, and will monitor these relationships over time. No treatment or intervention will be applied, and the total participation duration is not specified.